Target Dosing of Docetaxel Through Pharmacokinetic/Pharmacodynamic Optimisation of the First Chemotherapeutic Cycle

NCT00703378 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Solid Tumors

Interventions

DRUG: Docetaxel (Taxotere®)

Sponsor

National University Hospital, Singapore